Table 1 Characteristics of patients with chronic hepatitis B in the immune tolerance phase.

From: Noninvasive diagnosis model for predicting significant liver inflammation in patients with chronic hepatitis B in the immune-tolerant phase

Characteristics

Training set

N = 322

Validation set

N = 213

P value

Age(years)

35.0(29.0–43.0)

36.0(29.0–44.0)

0.218

Sex (%)

  

0.552

Male

159(49.4)

114(53.5)

 

PT (s)

11.9(11.3–12.8)

11.9(11.3–12.7)

0.968

INR

1.01(0.97–1.07)

1.02(0.97–1.07)

0.547

WBC (×109/L)

5.7(4.8–6.9)

5.5(4.6–6.6)

0.221

Hb (×109/L)

142.0(131.2–153.0)

143.0(131.0-156.0)

0.961

PLT (×109/L)

201.0(167.2-234.8)

192.0(160.0-231.0)

0.321

ALB (g/L)

43.8(40.8–46.1)

44.1(41.4–46.5)

0.391

GLB (g/L)

27.9(24.9–30.6)

28.0(25.4–30.3)

0.501

ALT (U/L)

26.0(20.0-33.8)

27.0(20.0–33.0)

0.598

AST (U/L)

24.0(20.0–30.0)

24.0(21.0–29.0)

0.253

GGT (U/L)

17.0(14.0–24.0)

17.0(14.0–24.0)

0.406

ALP (U/L)

71.0(59.0–87.0)

71.0(60.0–89.0)

0.988

TBIL (umol/L)

13.0(10.0-16.6)

12.1(9.6–16.0)

0.969

HBVDNA (Log10 IU/ml)

7.9(7.3–8.5)

7.8(7.0-8.3)

0.105

Liver inflammation grade (%)

  

0.978

G0

5(1.5)

5(2.3)

 

G1

198(61.5)

129(60.6)

 

G2

101(31.4)

67(31.5)

 

G3

15(4.7)

10(4.7)

 

G4

3(0.9)

2(0.9)

 

Fibrosis stage (%)

  

0.978

S0

93(28.9)

64(30.1)

 

S1

142(44.1)

94(44.1)

 

S2

67(20.8)

41(19.2)

 

S3

12(3.7)

8(3.8)

 

S4

8(2.5)

6(2.8)

 
  1. PT: Prothrombin; INR: International normalized ratio; WBC: White blood cell; PLT: Platelet; ALB: Albumin; GLB: Globulin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Glutamyl transpeptidase; ALP: Alkaline phosphatase; TBIL: Total bilirubin; HBV DNA, Hepatitis B virus DNA;
Back to article page